SGK1 Antibody (YA5450)
(Synonyms: SGK1)SGK1 Antibody (YA5450) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to SGK1.
-
Host:
Mouse
-
Application:
IHC-P, ICC/IF
-
Reactivity :
Human, Rat, Mouse
-
Formulation:
Supplied in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
-
Conjugation:
Non-conjugated
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
Applications
| Application |
IHC-P
IHC-P: Immunohistochemistry-Paraffin
|
ICC/IF
ICC/IF: Immunocytochemistry/
Immunofluorescence |
|---|---|---|
| Dilution Ratio | 1:100-200 | 1:50-200 |
Product Details
SGK1 Antibody (YA5450) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to SGK1.
-
Host Mouse
-
Clonality Monoclonal
-
Species ReactivityHuman, Rat, Mouse
-
Observed Molecular WeightObserved band size: 45-60 kDa
Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
Synthetic Peptide of SGK1 at AA range of 350-430
affinity chromatography.
Non-conjugated
Unmodified
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Background
-
Function
SGK1 is a serum- and glucocorticoid-regulated AGC serine/threonine kinase that regulates membrane sodium channel expression and hormonal control of renal Na+ retention[1][2]. Mechanistically, SGK1 acts downstream of PI3K, PDK1, and mTORC2, while also functioning as an AKT-parallel PI3K effector with distinct SGK1-dependent pathways[3][4]. In immune models, mTORC2-activated SGK1 promotes TH2 differentiation through NEDD4-2-JunB regulation and represses IFN-γ through TCF-1, linking SGK1 signaling to asthma, viral infection, and tumor rejection models[1]. In cancer models, SGK1 sustains AKT-independent mTORC1 activation through TSC2 phosphorylation and supports PI3K-driven tumor development, proliferation, and survival[5][4]. Compared with related isoforms, SGK family kinases share PI3K regulation, but SGK3 contains a PX domain, whereas SGK1 lacks this lipid-binding module[6]. For experimental applications, SGK1 inhibition with GSK650394 reduced mantle cell lymphoma proliferation, invasion, migration, and xenograft growth, supporting SGK1 inhibitors as tools for pathway and disease-model studies[7].
-
Subcellular Localization
Cytoplasm; Nucleus; Endoplasmic reticulum membrane; Cell membrane; Mitochondrion; Cell membrane
-
Expression
Tissue_specificity:This gene is expressed in most tissues, with the highest expression level in the pancreas, followed by the placenta, kidneys, and lungs. Isomer 2 is expressed strongly in the brain and pancreas, and weakly in the heart, placenta, lungs, liver, and skeletal muscle.
Induction:Induced by a very large spectrum of stimuli distinct from glucocorticoids and serum. -
Isoforms & Post-Translational Modification
O00141 has 5 isomers: O00141-1: 48942 Da (predicted); O00141-2: 59904 Da (predicted); O00141-3: 50623 Da (predicted); O00141-4: 47910 Da (predicted); O00141-5: 52119 Da (predicted).
Regulated by phosphorylation (PubMed:10191262, PubMed:11096081, PubMed:18925875, PubMed:20338997, PubMed:36373794). Activated by phosphorylation on Ser-422 by mTORC2, transforming it into a substrate for PDPK1 which phosphorylates it on Thr-256 (PubMed:10191262, PubMed:18925875, PubMed:20338997, PubMed:36373794). Phosphorylation on Ser-397 and Ser-401 are also essential for its activity (PubMed:19068477). Phosphorylation on Ser-78 by MAPK7 is required for growth factor-induced cell cycle progression (PubMed:11254654);Ubiquitinated by NEDD4L; which promotes proteasomal degradation. Ubiquitinated by SYVN1 at the endoplasmic reticulum; which promotes rapid proteasomal degradation and maintains a high turnover rate in resting cells. Isoform 2 shows enhanced stability -
Subunit
Homodimer; disulfide-linked. Forms a trimeric complex with FBXW7 and NOTCH1. Interacts with MAPK3/ERK1, MAPK1/ERK2, MAP2K1/MEK1, MAP2K2/MEK2, NEDD4, NEDD4L, MAPT/TAU, MAPK7, CREB1, SLC9A3R2/NHERF2 and KCNJ1/ROMK1. Associates with the mammalian target of rapamycin complex 2 (mTORC2) via an interaction with MAPKAP1/SIN1
-
SwissProt ID
-
Synonyms
SGK1
Documentation
References
[1]. Heikamp EB, et al. The AGC kinase SGK1 regulates TH1 and TH2 differentiation downstream of the mTORC2 complex. Nat Immunol. 2014 May;15(5):457-64. [Content Brief]
[2]. Mansley MK, et al. Dexamethasone and insulin activate serum and glucocorticoid-inducible kinase 1 (SGK1) via different molecular mechanisms in cortical collecting duct cells. Physiol Rep. 2016 May;4(10):e12792. [Content Brief]
[3]. Di Cristofano A. SGK1: The Dark Side of PI3K Signaling. Curr Top Dev Biol. 2017;123:49-71. doi: 10.1016/bs.ctdb.2016.11.006. Epub 2016 Dec 15. PMID: 28236975; PMCID: PMC5658788. et al. SGK1: The Dark Side of PI3K Signaling. Curr Top Dev Biol. 2017;123:49-71. [Content Brief]
[4]. Castel P, et al. PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition. Cancer Cell. 2016 Aug 8;30(2):229-242. [Content Brief]
[5]. Orlacchio A, et al. SGK1 Is a Critical Component of an AKT-Independent Pathway Essential for PI3K-Mediated Tumor Development and Maintenance. Cancer Res. 2017 Dec 15;77(24):6914-6926. [Content Brief]
[6]. Tessier M, et al. Serum and glucocorticoid-regulated protein kinases: variations on a theme. J Cell Biochem. 2006 Aug 15;98(6):1391-407. [Content Brief]
[7]. Li J, et al. The Serum- and Glucocorticoid-Inducible Kinase 1 (SGK1) as a Novel Therapeutic Target in Mantle Cell Lymphoma. Cancer Control. 2022 Jan-Dec;29:10732748221143881. [Content Brief]
Powered by Bioz
